Should We Assess Substance Use Prior to Patients Starting HCV Treatment?

Module number
Date presented
September 13, 2016 
Duration
57:40 
Audience
HCV providers and multi-disciplinary team staff members 
CE Credit
ELF 

On Tuesday, Sept 13th at 4:30PM EST, Dr. Jeffrey Weiss, PhD, of the Icahn School of Medicine at Mount Sinai presented on:  “Should we assess substance use prior to patients starting HCV treatment?“

This webinar was sponsored by the Empire Liver Foundation, an organization dedicated to increasing community awareness of liver disease and providing education on liver disease to health care providers and patients. If you would like to receive continuing education (CE) for this webinar, click here. If you have any questions about receiving continuing education, please contact megchappell@empireliverfoundation.org

About Dr. Weiss:
Dr. Weiss is an Associate Professor in the Department of Medicine, Assistant Professor in the Department of Psychiatry, and Director of the Hepatitis C Clinical & Research Program in the Division of General Internal Medicine at the Icahn School of Medicine at Mount Sinai.

Dr. Weiss has worked for over 20 years in the United States and Europe as a licensed clinical psychologist providing care to persons with infectious diseases and conducting research on how behavioral interventions can improve their quality and length of life. He has developed the Psychosocial Readiness Evaluation and Preparation for Hepatitis C Treatment (PREP-C), an open-access web-based provider tool to assess patient readiness to begin treatment for Hepatitis C infection.

Click here for instructions on how to receive CE credit